determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the …

Randomised controlled trials (RCTs) provide the reference standard for comparing the
efficacy of one therapy or intervention with another. However, RCTs have restrictive …

Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …

All pivotal trials have evaluated non–vitamin K oral antagonists (NOACs) against warfarin.
However, in some regions of the world, phenprocoumon is the most widely used vitamin K …

Aims: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non–
vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in …

Aim: To analyze the effectiveness and safety of direct oral anticoagulants (DOACs) in atrial
fibrillation (AF) patients attended in clinical practice. Methods: Observational and …

Новые пероральные антикоагулянты (НОАК) прямой ингибитор тромбина дабигатран,
селективные ингибиторы фактора Xaривароксабан и апиксабан все шире …

The effectiveness and safety of acute venous thromboembolism (VTE) treatment with
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …

Preventing thromboembolic events, while minimizing bleeding risks, remains challenging
when managing patients with atrial fibrillation (AF). Several factors contribute to current …

Introduction Following successful phase-III trials, direct oral anticoagulants such as
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …